Condition: Non-Hodgkin Lymphoma · Sponsor: University of Cologne
Pilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in patients ineligible for HCT-ASCT with Primary Central Nervous System Lymphoma (PCNSL)
This description comes directly from the study's public registry record.
Peter Borchmann, Prof. Dr. med. · +49221478 · MTR2-Studienteam@uk-koeln.de
Jan Michel Heger, Dr. med. · +49221478 · MTR2-Studienteam@uk-koeln.de
Always discuss trial participation with your own doctor first.
| Klinikum Stuttgart - Katharienenhospital | Stuttgart, Baden-Wurttemberg, Germany | Recruiting |
| Universitätsklinikum Freiburg | Freiburg im Breisgau, Baden-Würtemberg, Germany | Not Yet Recruiting |
| University of Cologne | Cologne, Germany, Germany | Not Yet Recruiting |
| Universitätsklinikum Hamburg-Eppendorf | Hamburg, Hamurg, Germany | Not Yet Recruiting |
| Universitätsklinikum Essen | Essen, Nordrhein Westphalen, Germany | Not Yet Recruiting |
| Charité - Universitätsmedizin Berlin | Berlin, State of Berlin, Germany | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05583071